It would also be relevant in future studies to evaluate the levels of pro- and pre-pro BDNF isoforms in order to assess their distribution following STZ treatment and determine whether there is an increase in the pathogenic pro-BDNF isoform, which is known to be involved in neurotoxic pathways associated with AD. Here, BDNF is linked to Alzheimer disease.